Clovis Oncology is an American

pharmaceutical company The pharmaceutical industry is a Medicine, medical industry that discovers, develops, produces, and markets pharmaceutical goods such as medications and medical devices. Medications are then administered to (or Self-medicate, self-administered b ...

which mainly markets products for treatment in

oncology Oncology is a branch of medicine that deals with the study, treatment, diagnosis, and prevention of cancer. A medical professional who practices oncology is an ''oncologist''. The name's Etymology, etymological origin is the Greek word ὄγ ...

. Clovis was founded in 2009 and is headquartered in

Boulder, Colorado Boulder is a List of municipalities in Colorado#Home rule municipality, home rule city in Boulder County, Colorado, United States, and its county seat. With a population of 108,250 at the 2020 United States census, 2020 census, it is the most ...

. The company is a publicly traded company on

NASDAQ The Nasdaq Stock Market (; National Association of Securities Dealers Automated Quotations) is an American stock exchange based in New York City. It is the most active stock trading venue in the U.S. by volume, and ranked second on the list ...

under the symbol CLVS and is in the

NASDAQ Biotechnology Index The NASDAQ Biotechnology Index is a stock market index made up of securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either the Biotechnology or the Pharmaceutical industry. A list of the 225 comp ...

with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for

Chapter 11 bankruptcy Chapter 11 of the United States Bankruptcy Code ( Title 11 of the United States Code) permits reorganization under the bankruptcy laws of the United States. Such reorganization, known as Chapter 11 bankruptcy, is available to every business, w ...

History

Clovis Oncology was founded in 2009 by Patrick Mahaffy in

. The company was named in honor of the Mahaffy cache, a collection of Clovis period stone tools dated to 11,000 BCE, discovered in the front yard of Mahaffy's home in Boulder.

Product development

Rociletinib

The company was developing rociletinib, as a treatment for

non-small cell lung cancer Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitiv ...

. A phase III trial was completed in April 2016Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%. April 2016
/ref> and had it been approved it would have competed with AstraZeneca's Tagrisso (

osimertinib Osimertinib, sold under the brand name Tagrisso, is a medication used to treat non-small-cell lung carcinomas with specific mutations. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The most common side e ...

). According to the company web site as of November 2016 studies on the drug are no longer accepting new patients, but Clovis would continue to supply the drug to patients whose physicians had recommended continued treatment. In September 2018, the company and two former executives agreed to a $20 million settlement with the

Securities and Exchange Commission The United States Securities and Exchange Commission (SEC) is an independent agency of the United States federal government, created in the aftermath of the Wall Street crash of 1929. Its primary purpose is to enforce laws against market m ...

on claims it exaggerated to investors the efficacy of Roci in patient trials.

Rucaparib

Rucaparib Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is taken by mouth. The ...

is a

PARP inhibitor PARP inhibitors are a class of drugs that are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP), which plays a role in repairing DNA in damaged cells. Medical uses of these drugs include the treatment of heri ...

in Phase II and III clinical trials for advanced

ovarian cancer Ovarian cancer is a cancerous tumor of an ovary. It may originate from the ovary itself or more commonly from communicating nearby structures such as fallopian tubes or the inner lining of the abdomen. The ovary is made up of three different ...

. In December 2016, the

Food and Drug Administration The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respo ...

granted an

accelerated approval The United States Food and Drug Administration (FDA) initiated the FDA Accelerated Approval Program in 1992 to allow faster approval of drugs for serious conditions that fill an unmet medical need. The faster approval relies on use of surrogate end ...

for the use of rucaparib "for the treatment of patients with deleterious

BRCA mutation A ''BRCA'' mutation is a mutation in either of the ''BRCA1'' and ''BRCA2'' genes, which are tumour suppressor genes. Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, ...

(

germline In biology and genetics, the germline is the population of a multicellular organism's cells that develop into germ cells. In other words, they are the cells that form gametes ( eggs and sperm), which can come together to form a zygote. They dif ...

and/or

somatic Somatic may refer to: * Somatic (biology), referring to the cells of the body in contrast to the germ line cells ** Somatic cell, a non-gametic cell in a multicellular organism * Somatic nervous system, the portion of the vertebrate nervous syst ...

)-associated advanced ovarian cancer who have been treated with two or more

chemotherapies Chemotherapy (often abbreviated chemo, sometimes CTX and CTx) is the type of cancer treatment that uses one or more anti-cancer drugs ( chemotherapeutic agents or alkylating agents) in a standard regimen. Chemotherapy may be given with a cura ...

". In 2023, rucaparib was sold to Pharmaand GmbH (Pharma&) as part of Clovis's bankruptcy proceedings.

Lucitanib

Lucitanib Lucitanib (International Nonproprietary Name, INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. It is a protein kinase inhibitor that bl ...

is a

VEGFR inhibitor VEGF receptors (VEGFRs) are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. Depending on alternative splicing, they may be membrane-bound (mbVEGFR) or soluble (sVEGFR). I ...

. It is also an inhibitor of FGFR1 and

FGFR2 Fibroblast growth factor receptor 2 (FGFR-2) also known as CD332 (cluster of differentiation 332) is a protein that in humans is encoded by the ''FGFR2'' gene residing on chromosome 10. FGFR2 is a receptor for fibroblast growth factor. FGFR-2 is ...

and has undergone clinical trials for advanced solid tumors.

References

{{Authority control Pharmaceutical companies of the United States Companies that filed for Chapter 11 bankruptcy in 2022